NeuroTell

NeuroTell is a Swiss biotechnology company and EPFL spin-off that leverages advanced brain simulation technology and artificial intelligence to transform central nervous system (CNS) drug discovery. Originating from the Blue Brain Project, the company provides a platform that predicts the clinical efficacy and safety of drug candidates by simulating their effects on detailed digital models of the human brain. This approach allows pharmaceutical partners to identify promising leads and optimize clinical trial designs, potentially reducing the high failure rates associated with neurology and psychiatry drug development. NeuroTell's technology integrates electrophysiology, machine learning, and large-scale neural modeling to provide deep insights into brain-wide drug interactions.